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Abstract The purpose of this investigation was to study
risk factors for Clostridium difficile infection (CDI) in an
endemic setting. In a 34-month prospective case–control
study, we compared the risk factors and clinical character-
istics of all consecutively diagnosed hospitalised CDI
patients (n=93) with those of patients without diarrhoea
(n=76) and patients with non-CDI diarrhoea (n=64). The
incidence of CDI was 17.5 per 10,000 hospital admis-
sions. C. difficile polymerase chain reaction (PCR)
ribotype 014 was the most frequently found type
(15.9%), followed by types 078 (12.7%) and 015
(7.9%). Independent risk factors for endemic CDI were
the use of second-generation cephalosporins, previous
hospital admission and previous stay at the intensive care
unit (ICU). The use of third-generation cephalosporins
was a risk factor for diarrhoea in general. We found no
association of CDI with the use of fluoroquinolones or
proton pump inhibitors (PPIs). The overall 30-day
mortality among CDI patients, patients without diarrhoea
and patients with non-CDI diarrhoea was 7.5%, 0% and
1.6%, respectively. In this endemic setting, risk factors for
CDI differed from those in outbreak situations. Some risk
factors that have been ascribed to CDI earlier were, in this
study, not specific for CDI, but for diarrhoea in general.
The 30-day mortality among CDI patients was relatively
high.
Introduction
Since 2002, outbreaks caused by Clostridium difficile
infection (CDI) have been reported in Canada, the USA
and Europe, associated with the emergence of a new
hypervirulent type. This type has been characterised as
North American pulsed-field type 1, restriction endonucle-
ase analysis group type BI, toxinotype III and polymerase
chain reaction (PCR) ribotype 027 (type 027) [1–5]. During
outbreaks in the USA and Canada, the reported incidences
of CDI varied between 155 and 225 per 10,000 hospital
admissions [3, 6]. Peak incidences of CDI due to type 027
during outbreaks in the Netherlands were remarkably lower,
around 50 per 10,000 hospital admissions [7, 8].
Most recent studies on the risk factors of CDI focussed on
outbreaks, whereas less is known about CDI in settings with a
low incidence.Well described riskfactors for CDI inoutbreak
situations are prior use of antibiotics, increased disease
severity and, in case of outbreaks caused by type 027,
advanced age and prior use of fluoroquinolones [9–11].
The aim of our study was to identify risk factors for CDI
in a true endemic setting. A second aim was to establish
risk factors specific for CDI, in comparison with factors for
diarrhoea in general. To answer these questions, we
performed a prospective case–control study at the Leiden
University Medical Center, the Netherlands, during a period
of 34 months.
Methods
Patients
From July 2006 through April 2009, all hospitalised
patients with CDI were included in the study. Tests for
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unformed faecal samples from patients admitted for two
days or more, regardless of the physicians’ requests. For
each hospitalised CDI patient, two controls were included,
matched for the ward at which CDI was diagnosed and the
time of admission. The controls included one control
patient without diarrhoea (control patient) and one control
patient with diarrhoea and a negative C. difficile toxin test
(non-CDI patient). Controls were consecutive patients on
the alphabetical ward list.
Definitions
Definitions as proposed by the European and American
Centres of Disease Control were used [2, 12]. Diarrhoea
was defined as ≥3 unformed stools per 24-h period. CDI
was defined as the presence of diarrhoea in combination
with a positive toxin test for C. difficile. A community
association was defined as the development of CDI
outside the hospital or within 48 h after admission,
without a history of admission in the previous 3 months.
We defined diarrhoea as severe when it occurred with
one or more of the following: bloody stools, hypovolae-
mia, fever (T>38.0°C) and leukocytosis (>12.0 × 10
9/l),
hypo-albuminaemia (<20 g/l) or pseudomembranous coli-
tis. A complicated course of CDI was defined as:
admission to the intensive care unit (ICU), a surgical
intervention in association with CDI or death within one
month. Mortality was considered to be contributable to
CDI when a patient died during admission, partly due to
the consequences of CDI.
Isolation and characterisation of Clostridium difficile
C. difficile toxins in stools were detected by VIDAS C.
difficile toxin A during the first 12 months of the study and
VIDAS toxin A/B assay during the ensuing 22 months
(bioMérieux, France). Each positive sample was cultured.
Available isolates were identified as C. difficile using a
PCR assay to detect the presence of gluD and were PCR
ribotyped as previously described [8, 13].
Data collection
Approval was obtained from the Medical Review Ethics
Committee to collect demographical and clinical patient
data. Information was collected on patients’ age, sex, co-
morbidity, ward of acquisition, disease severity, clinical
course and mortality. Furthermore, data were collected on
surgery, invasive procedures, admissions, use of antibiotics
and other medications in the 3 months prior to CDI. We
gathered this information through consultation of the
physician in charge, as well as by using patient records
and the hospital electronic medical information system. The
period of 3 months prior to CDI was determined by
calculating backwards from a reference date. For CDI and
non-CDI patients, this reference date was defined as the day
on which the diarrhoea started. The reference date for
control patients was determined by adding the hospitalised
period of the matched CDI patient (time between admission
and start of diarrhoea) to the admission date of the control
patient. Co-morbidity was assessed by both the Charlson
co-morbidity index and the ICD-10 classification in ten
disease groups, as mentioned in Table 1 [14].
Statistical analysis
Continuous data were compared between groups using
the t-test. Pearson’s Chi-square test and Fisher’se x a c tt e s t
were used for the analysis of proportions. Factors that
were associated in the univariate analysis (UVA) with a p-
value <0.10, as well as putative risk factors from earlier
studies, were analysed in a multi-variable model. Here,
associations were always adjusted for age, sex, ward and
Charlson co-morbidity index. To evaluate the effect of
medications and interventions on (CDI) diarrhoea, we
performed additional adjustments for co-medication and
other interventions. When comparing non-CDI patients
with control patients, we also corrected for the time between
admission and the reference date. Relative risks were
estimated as odds ratios (ORs) and presented with a 95%
confidence interval (95% CI). Statistical significance was
reached with a two-sided p-value <0.05; trends were defined
by a p-value <0.10. All analyses were performed using the
SPSS for Windows software package, version 17.0.
Results
During the 34-month study period, 93 patients were
diagnosed with CDI. The incidence varied from 0 to 43
per 10,000 hospital admissions, with an average of 17.5.
During this period, no outbreaks were observed. CDI was
community-associated in four patients (4.3%). Most
patients (n=30; 32.3%) were hospitalised at the Department
of Internal Medicine, followed by the general surgery ward
(n=15; 16.1%). Eighty-nine CDI patients were positive on
both toxin testing and culture (95.7%). Isolates from 63
(67.7%) patients were available for PCR ribotyping: type
014 was the most frequently found type (n=10; 15.9%),
followed by types 078 (n=8; 12.7%) and 015 (n=5; 7.9%).
Type 027 was not present. Three patients with CDI had a co-
infectionwithanenterovirus,norovirusandCryptosporidium,
respectively.
The 93 CDI patients were compared to 76 control
patients and 64 patients with non-CDI diarrhoea. Of all
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however, in some cases (the exact number is depicted in the
footnotes of Table 1), no information about the use of
nasogastric intubation, surgery or endoscopy was noted.
In the group of non-CDI patients, two patients were
diagnosed with a rotavirus and Giardia lamblia, respec-
tively. Among the other 62 patients, no causal agent was
found. CDI patients had a median age of 56 years; non-CDI
diarrhoea and control patients had a median age of 50 years.
Of the CDI patients, 60% were male, compared to 50% and
54% of the non-CDI and control patients, respectively. The
time span between admission and the start of diarrhoea did
not significantly differ between CDI and non-CDI patients.
Characteristics and risk factors
We present the baseline characteristics and risk factors for
CDI and non-CDI diarrhoea in Tables 1 and 2. The use of
antibiotics as a risk factor for CDI and non-CDI is depicted
in Table 3. All of the following results reached statistical
significance in the multi-variable analysis (MVA), unless
otherwise stated.
Table 1 Baseline characteristics of patients with Clostridium difficile infection (CDI), patients with non-CDI diarrhoea and control patients
Risk factors CDI patients (n=93)
a Non-CDI patients (n=64)
b Control patients (n=76)
c
n (%) n (%) n (%)
Age>65 years 33 (35.5) 18 (28.1) 18 (23.7)
Male sex 56 (60.2) 32 (50.0) 41 (53.9)
Charlson co-morbidity index
0 14 (15.1) 12 (18.8) 19 (25.0)
1–2 38 (40.9) 26 (40.6) 32 (42.1)
3–4 28 (30.1) 15 (23.4) 18 (23.7)
5+ 13 (14.0) 11 (17.2) 7 (9.2)
Any underlying disease 90 (96.8) 61 (95.3) 70 (92.1)
Malignancy 24 (26.1) 18 (28.1) 21 (27.6)
Solid tumour 10 (10.9) 5 (7.8) 11 (14.5)
Haematologic malignancy 15 (16.1) 13 (20.3) 10 (13.2)
Endocrine diseases 26 (28.0) 16 (25.0) 20 (26.3)
Respiratory tract diseases 14 (15.1) 9 (14.1) 8 (10.5)
Gastro-intestinal tract diseases 36 (38.7) 16 (25.0) 21 (27.6)
Cardiovascular tract diseases 42 (45.2) 27 (42.2) 30 (39.5)
Urogenital tract diseases 42 (45.2) 21 (32.8) 24 (31.6)
Nervous system diseases 6 (6.5) 4 (6.2) 6 (7.9)
Infectious diseases 13 (14.3) 6 (9.4) 7 (9.2)
Muscular/connective tissue diseases 10 (10.8) 4 (6.2) 7 (9.2)
Other diseases 36 (39.1) 24 (37.5) 22 (28.9)
Use of any antibiotics 87 (93.5) 48 (75.0) 51 (68.0)
Proton pump inhibitors (PPIs) 64 (68.8) 39 (56.2) 38 (50.0)
NSAIDs 11 (11.8) 3 (4.7) 7 (9.2)
Immunosuppressive agents 54 (58.8) 38 (59.4) 34 (44.7)
Cytostatic agents 21 (22.6) 13 (20.3) 11 (14.5)
Nasogastric tube 39 (44.3) 29 (45.3) 20 (28.2)
Abdominal surgery 35 (37.6) 24 (37.5) 20 (28.6)
Endoscopy 28 (31.5) 16 (25.0) 10 (13.2)
Previous admission 68 (74.7) 19 (30.2) 30 (41.7)
Previous admission to ICU 26 (28.0) 12 (18.8) 5 (6.6)
ICU intensive care unit;NSAIDs non-steroidal anti-inflammatory drugs
an between 88 and 93
bn between 62 and 64
cn between 71 and 76
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Severe diarrhoea was present among 51 hospitalised
patients with CDI (58.6%) and 25 patients with non-CDI
diarrhoea (39.7%) (OR 2.22; 95% CI 1.14–4.30). No
significant differences between CDI and non-CDI diar-
rhoeal patients were found regarding the frequency of fever
(55.6% vs. 43.3%), bloody stools (12.2% vs. 12.9%) or
Table 2 Crude and adjusted odds ratios (ORs) for the development of CDI and non-CDI diarrhoea
Risk factors CDI vs. control Non-CDI vs. control
Crude odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Crude odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Age>65 years 1.77 (0.90–3.49)
a 1.82 (0.92–3.62)
a 1.26 (0.59–2.69) 1.17 (0.54–2.55)
Male sex 1.29 (0.70–2.39) 1.30 (0.70–2.43) 0.85 (0.44–1.67) 0.88 (0.45–1.72)
Charlson co-morbidity index
0 Reference Reference Reference Reference
1–2 1.61 (0.70–3.72) 1.78 (0.73–4.37) 1.29 (0.53–3.13) 1.35 (0.50–3.66)
3–4 2.11 (0.85–5.24) 2.42 (0.87–6.73)
a 1.32 (0.49–3.57) 1.32 (0.41–4.30)
5+ 2.52 (0.80–7.95) 2.57 (0.76–8.65) 2.49 (0.76–8.19) 3.10 (0.82–11.7)
a
Any underlying disease 2.57 (0.62–10.7) 2.45 (0.58–10.4) 1.74 (0.42–7.27) 2.10 (0.46–9.56)
Haematologic malignancy 1.27 (0.54–3.01) 2.33 (0.86–6.23)
a 1.68 (0.68–4.15) 2.19 (0.70–6.88)
Urogenital tract diseases 1.78 (0.95–3.36)
a 1.97 (0.97–4.02)
a 1.06 (0.52–2.16) 0.99 (0.42–2.34)
Other diseases 1.58 (0.83–3.02) 1.47 (0.72–3.00)
a 1.47 (0.73–2.99) 1.41 (0.65–3.07)
Use of any antibiotics 6.82 (2.62–17.8)
b 5.41 (1.79–16.3)
b 1.41 (0.67–2.98) 0.99 (0.40–2.42)
Proton pump inhibitors (PPIs) 2.21 (1.18–4.14)
b 1.14 (0.51–2.58) 1.29 (0.66–2.51) 1.01 (0.46–2.22)
NSAIDs 1.32 (0.49–3.60) 0.86 (0.27–2.73) 0.49 (0.12–1.96) 0.34 (0.07–1.57)
Immunosuppressive agents 1.71 (0.93–3.15)
a 1.39 (0.64–3.06) 1.81 (0.92–3.54)
a 1.44 (0.64–3.22)
Cytostatic agents 1.72 (0.77–3.85) 1.61 (0.61–4.24) 1.51 (0.62–3.64) 1.64 (0.58–4.63)
Nasogastric tube 2.03 (1.04–3.95)
b 1.50 (0.66–3.43) 2.11 (1.04–4.31)
b 1.77 (0.70–4.50)
Abdominal surgery 1.51 (0.77–2.94) 1.17 (0.56–2.45) 1.50 (0.73–3.10) 1.28 (0.57–2.84)
Endoscopy 3.03 (1.36–6.75)
b 2.64 (1.00–6.96)
a 2.20 (0.92–5.27)
a 2.63 (0.90–7.64)
a
Previous admission 4.14 (2.13–8.05)
b 4.49 (2.23–9.01)
b 0.61 (0.30–1.23) 0.55 (0.26–1.17)
Previous admission to ICU 5.51 (2.00–15.2)
b 5.47 (1.95–15.3)
b 3.28 (1.09–9.87)
b 2.64 (0.83–8.37)
a
ICU intensive care unit;NSAIDs non-steroidal anti-inflammatory drugs
aTrend detected (p<0.10)
bSignificant difference (p<0.05)
Table 3 The use of antibiotics expressed in defined daily doses (DDDs) in patients with CDI and non-CDI diarrhoea and control patients
Antibiotics CDI patients
(n=93)
a
Non-CDI patients
(n=64)
a
Control patients
(n=76)
a
CDI vs. control Non-CDI vs. control
n (%) n (%) n (%) Crude odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)
Crude odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)
Cephalosporins
First generation 13 (14.0) 5 (7.8) 12 (16.0) 0.85 (0.36–2.00) 0.79 (0.21–3.02) 0.45 (0.15–1.34) 0.18 (0.04–0.84)
b
Second
generation
46 (49.5) 20 (31.3) 14 (21.5) 4.26 (2.10–8.67)
b 7.64 (2.42–24.2)
b 1.98 (0.90–4.34) 0.97 (0.31–3.05)
Third generation 29 (31.2) 12 (18.8) 2 (3.1) 16.5 (3.80–72.1)
b 20.4 (3.50–119)
b 8.42 (1.81–39.2)
b 9.53 (1.66–54.7)
b
Penicillins 51 (54.8) 22 (34.4) 23 (30.7) 2.75 (1.45–5.20)
b 1.47 (0.58–3.72) 1.18 (0.58–2.41) 0.69 (0.27–1.74)
Fluoroquinolones 31 (33.3) 21 (32.8) 20 (26.7) 1.38 (0.70–2.69) 0.57 (0.20–1.62) 1.34 (0.65–2.79) 0.93 (0.32–2.70)
Clindamycin 5 (5.4) 2 (3.1) 1 (1.3) 4.21 (0.48–36.8) 0.75 (0.03–17.2) 2.39 (0.21–27.0) 2.68 (0.14–50.2)
Vancomycin 22 (23.7) 14 (21.9) 7 (9.3) 3.01 (1.21–7.50)
b 0.51 (0.11–2.40) 2.72 (1.02–7.23)
b 1.55 (0.43–5.62)
aThis information was known for all patients, except one control patient
bSignificant difference (p<0.05) detected
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however, have a higher white blood cell count (≥15 ×
10
9/l: 49.9% vs. 30.0%, OR 2.28; 95% CI 1.13–4.59). Most
patients with CDI were treated with metronidazole (n=57;
63.3%), two patients (2.2%) were treated with vancomycin
and in 27 patients (30.0%), no specific CDI treatment was
initiated. The 30-day and 60-day mortality rates are
depicted in Fig. 1. At one month follow-up, a complicated
course was observed in nine CDI patients (10.3%),
comprising two colectomies, four ICU admissions due to
CDI and seven deaths (7.5%). CDI contributed directly to
three of these deaths, but was not the primary cause. One
non-CDI patient (1.6%) and none of the control patients
died at one month follow-up. No significant associations
were detected between the severity of the diarrhoea,
treatment or outcome.
Discussion
Inthis34-monthprospectivecase–controlstudy,risk factors for
CDI were studied in an endemic setting with a low incidence
rate of CDI. The inclusion of a control group of patients with
diarrhoea, tested negative for CDI, enabled us to discriminate
between risk factors for CDI and for diarrhoea in general.
Common risk factors for CDI outbreaks, such as age
above 65 years and a high co-morbidity index, were
recognised as trends in our study. This may be due to the
fact that these risk factors are of less importance in endemic
settings, resulting in a lack of power to discern these risk
factors. Other well known risk factors for CDI, such as the
use of second-generation cephalosporins and previous (ICU)
admission, were also found in this endemic situation [3, 10,
15]. Conversely, the use of fluoroquinolones or proton pump
inhibitors (PPIs) was not a risk factor for CDI. Furthermore,
the previous use of third-generation cephalosporins was a
risk factor for diarrhoea in general.
The CDI incidence in our hospital was lower than that
described in other studies in endemic situations, but
comparable to the incidence of 18 per 10,000 hospital
admissions found in other Dutch hospitals [16]. Recently, a
retrospective study analysing risk factors for CDI in an
endemic setting in the USA reported an incidence rate of
CDI of 106 per 10,000 hospital admissions, which is a
factor of 5 higher than what we found in this study [10].
There seems to be a considerable difference, per hospital
and per country, in the application of the definition of
endemic CDI. Therefore, reported rates of endemic CDI
may merely reflect a baseline incidence.
In outbreak situations, the previous use of fluoroquinolones
has been recognised as an important risk factor for CDI [9, 11,
17, 18]. This association may be due to disruption of the gut
flora by newer fluoroquinolones or the high fluoroquinolone
resistance found among hypervirulent type 027 strains [19].
Although fluoroquinolones (mainly ciprofloxacin) were fre-
quently prescribed in this study, we found no association with
CDI. An explanation could be that we did not encounter type
027 in our hospital. The most frequently found PCR
ribotypes in our study (types 014, 078 and 015) are
commonly found in the Netherlands and Europe, and are
more susceptible to fluoroquinolones than type 027 [11].
The use of vancomycin was previously recognised as a
risk factor for endemic CDI [10]. Instead, in this study, the
association between vancomycin and CDI was strongly
confounded by the concomitant use of second- and,
especially, third-generation cephalosporins (the combina-
tion is part of the in-house empirical sepsis therapy) and
was not a risk factor for CDI.
PPIsraisethegastricpH,whichisassociatedwithenhanced
bacterial colonisation of first part of the gastro-intestinal tract.
Studies on the use of PPIs in association with CDI revealed
conflicting conclusions [20, 21]. In our study, we found no
association of the use of PPIs with CDI. It should be noted
that half of the non-CDI and control patients also used PPIs.
Earlier studies have found high contamination and
colonisation rates with C. difficile spores in the hospital
environment, among hospitalised patients and asymptom-
atic carriers [22, 23]. A high colonisation pressure on a
ward (exposure in time to multiple colonised or infected
patients) is associated with an increased risk of CDI [10].
To ensure that CDI and control patients were exposed to a
similar colonisation pressure, we selected control patients
from the same ward as CDI patients using the same time
period between admission and reference date [24].
Fig. 1 Survival curve of patients with Clostridium difficile infection
(CDI), non-CDI diarrhoea and control patients in a period of 60 days
after the reference date
Eur J Clin Microbiol Infect Dis (2011) 30:587–593 591We observed a contributable and overall mortality of
3.2% and 7.5% after 30 days follow-up, respectively. These
proportions are in between the overall 30-day mortality of
4.7%, found in an endemic setting in Canada, and 20%
mortality after 60 days in a USA study [25, 26]. These
mortality rates are much lower than those reported during
outbreaks caused by the type 027 strain [3, 11, 26, 27]. In
the Netherlands, a complicated course due to type 027 was
described in 12.5%, with an attributable mortality rate of
6.3% [9].
Our study has several limitations. First, we used the
presence of toxins in faeces as a screening test for CDI, which
is in agreement with the European recommendations [28]. An
alternative standard for diagnosing CDI is the detection of C.
difficile in faeces by toxinogenic culture or PCR. Application
of this definition could have resulted in a different case and
non-CDI control group. However, none of the patients with
non-CDI diarrhoea developed CDI at a later time during
admission, which was in accordance with the high negative
predictive value of our toxin test. Second, although the
endemic incidence found in our study is comparable to that
in other Dutch hospitals, it is lower than the incidence rates
reported in other studies in endemic situations, which can
imply that our findings may not be applicable to endemic
situations in other countries [8, 26, 29].
In conclusion, in this endemic setting, some risk factors for
CDI were similar to those found in outbreak situations, but
some risk factors that have been ascribed to CDI earlier were,
in this study, not specific for CDI, but for diarrhoea in general.
TheuseoffluoroquinolonesandPPIsdidnotinfluencetherisk
ofendemicCDI.CDIpatientsweremoreseverelyillthannon-
CDI diarrhoeal patients, as illustrated by a higher leukocyte
count and the relatively high 30- and 60-day mortality.
Because CDI is the most important cause of nosocomial
diarrhoea, more studies are needed in order to determine the
long-term outcome associated with C. difficile infections.
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